CompletedEUCTR 2016-002171-94
Effectiveness of a personalized Neurofeedback Training device (ADHD@Home) as compared with Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder...
This historical record does not confirm current site availability.
Historical research recordBelgium + Spain
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Spain
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 179
- Sponsor
- Mensia Technologies SA
- Sponsor type
- Other organization
- Study type
- Biological
- Intervention type
- Biological, Drug
- Study phase
- Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Belgium, Spain
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2016-002171-94
- Official title
Show the full official title
Effectiveness of a personalized Neurofeedback Training device (ADHD@Home) as compared with Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belgium · Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Mensia Technologies SA.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...